Antepartum fetal surveillance in diabetic pregnant patients.
The antepartum fetal surveillance (biochemical and biophysical) data of 140 pregnant diabetic patients were evaluated. We determined how often intervention occurred on the basis of abnormal tests and correlated each test with neonatal outcome. Fifteen of the total 140 patients had their pregnancies terminated because of abnormal biochemical and/or biophysical tests. An abnormal estriol (E3) value preceded the abnormal antepartum fetal heart rate testing in eight of 10 instances. We conclude that the major benefit of the antepartum fetal surveillance techniques, in this group of patients and under the present scheme, is in determining when not to intervene, thus allowing safe prolongation of pregnancy.
D004964:Estriol / Q000097:blood; D005260:Female; D005318:Fetal Heart; D005323:Fetal Monitoring; D005865:Gestational Age; D006339:Heart Rate; D006801:Humans; D007751:Labor, Induced; D011247:Pregnancy; D011254:Pregnancy in Diabetics
D004964:Estriol